A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.

A prespecified pooled FIDELITY analysis found that finerenone reduced cardiovascular and kidney composite outcomes in patients with CKD and type 2 diabetes, with benefits consistent regardless of SGLT2 inhibitor use.